ArticleClinical and translational allergy2022

Pharmacokinetic equivalence of CT-P39 and reference omalizumab in healthy individuals: A randomised, double-blind, parallel-group, Phase 1 trial.

Marcus Maurer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.